28 февраля, 17:13

5 Reasons Why Pfizer (PFE) Could be a Great Pick in 2018

Pfizer's (PFE) outperformance is backed by decent quarterly results, positive news flow and regulatory updates.

Выбор редакции
02 февраля, 17:12

The Zacks Analyst Blog Highlights: Pfizer, PayPal, Raytheon, Aetna and Kinder Morgan

The Zacks Analyst Blog Highlights: Pfizer, PayPal, Raytheon, Aetna and Kinder Morgan

02 февраля, 00:39

Top Analyst Reports for Pfizer, PayPal & Raytheon

Top Analyst Reports for Pfizer, PayPal & Raytheon

30 января, 18:10

Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat

Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.

30 января, 16:02

Pfizer (PFE) Q4 Earnings & Sales Top, 2018 View Upbeat

Pfizer (PFE) beat expectations for both earnings and revenues in Q4. It issued an upbeat guidance for 2018.

Выбор редакции
25 января, 23:51

Will Pfizer (PFE) Surpass Estimates This Earnings Season?

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.

25 января, 23:51

Will Pfizer (PFE) Surpass Estimates This Earnings Season?

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.

25 января, 18:47

Pfizer's Rituxan Biosimilar Meets Endpoint in Phase III

Pfizer's (PFE) biosimilar version of Roche's blockbuster leukemia drug, Rituxan/Mabthera, meets primary endpoint in phase III comparative trial.

22 декабря 2017, 16:48

The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

21 декабря 2017, 23:36

Top Research Reports for Pfizer, FedEx & Abbott

Top Research Reports for Pfizer, FedEx & Abbott

14 ноября 2017, 16:26

The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

06 ноября 2017, 16:32

Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah

It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.

31 октября 2017, 18:53

Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View

Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.

13 октября 2017, 15:06

Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

26 июля 2017, 17:11

Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?

While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.

Выбор редакции
03 июля 2017, 18:55

Why Investment In Biosimilars Is Important For Pfizer

Pfizer bought Hospira in 2015 to strengthen its generic drugs business, and gain a strong foothold in sterile injectables and the growing biosimilar market. It is Hospira’s biosimilar pipeline that holds to the most promise as far as Pfizer’s upside potential is concerned.

Выбор редакции
20 июня 2017, 16:30

The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

05 июня 2017, 10:18

Pfizer (PFE) Down 2.5% Since Earnings Report: Can It Rebound?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

26 мая 2017, 16:36

Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

18 мая 2017, 16:30

The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific

The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific